Falk Gastro Info 2/2026

Jairath V et al, Lancet Gastroenterol Hepatol. 2026;11(1):34-45

Bispecific antibody against TNF and IL-23 in ulcerative colitis: Treatment with SOR102, an orally administered bispecific antibody against TNF and IL-23, had few side effects in this phase 1 study and showed some efficacy in the treatment of ulcerative colitis.

Chen Y et al, Gut. 2025;75(1):72-80

Risk of metachronous neoplasia after polypectomy in patients < 50 years of age: Patients < 50 years of age undergoing polypectomy during a screening colonoscopy had a comparable risk of metachronous polyps with high-grade neoplasia as compared to older patients > 50 years of age in this prospective cohort study. Therefore, identical follow-up strategies can be used in both age groups.

Oh JH et al, J Hepatol. 2025;83(6):1256-1265

Time-restricted eating instead of calorie counting: New perspectives for the treatment of MASLD: A recent study from Korea shows that time-restricted eating (TRE) reduces fatty liver and body weight in patients with MASLD almost as effectively as traditional calorie restriction. The timing of the meals during TRE appears to be less relevant but rather the overall reduction in energy intake. Nevertheless, TRE could represent a practical and well-tolerated alternative for patients who have difficulty with continuous calorie counting.

Del Zompo F et al, J Hepatol. 2025;83(6):1305-1319

Novel therapeutic approach in primary sclerosing cholangitis: This study identifies the tight junction protein claudin-1 as a key mediator in the pathogenesis of primary sclerosing cholangitis (PSC) and demonstrates an association with disease activity and prognosis. In preclinical models, claudin-1 blockade led to a significant reduction in inflammation, cholestasis, and fibrosis. Thus, this study opens a promising therapeutic perspective for a disease for which there are currently no effective drug treatment options.

Billings LK et al, Lancet. 2025;406(10520):2631-2643

The amylin receptor agonist eloralintid – A new approach to the pharmacological treatment of obesity: In a placebo-controlled phase 2 study in patients with obesity, once-weekly subcutaneous administration of eloralintid over a period of 48 weeks resulted in weight loss of up to approx. 20%.

D'Haens GR et al, Lancet Gastroenterol Hepatol. 2026;11(1):12-21

Vedolizumab in early vs. late Crohn's disease (LOVE-CD): In this phase 4 study, treatment with vedolizumab was significantly more effective and had fewer side effects in patients with early Crohn's disease (disease duration < 2 years, naïve to advanced therapies) than in patients with longer disease duration (> 2 years, pretreated with immunomodulators and TNF antibodies). Clinical and endoscopic remission after 26 and 52 weeks was achieved in 31.4% vs. 8.6%.